Statistical Methods 5.2.1. General Methods • All statistical analysis and data summarization will be generated using SAS version 9.3 or later . • Unless otherwise stated, summary tables will be presented by treatment regimen (cohort) and overall . • No formal comparisons across treatment regimen (Cohort 1 vs. Cohort 2) will be performed. • Confidence intervals (CIs) will be presented at the 95% significance level • Continuous variables will be summarized using the number of observations (n), mean, standard deviation (SD), median, minimum, first quartile, third quartile, and maximum . Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 14 of 24 04MAY2018 • Categorical variables will be summarized using number of observations (n), frequency and percentages of subjects (percentages will not be shown when cell count is zero). • AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 15.0. • Concomitant medications will be coded using World Health Organization (WHO) Drug V ersion 1Q 2012. 5.2.2. Definitions • Age: (Informed Consent Date – Date of Birth)/365.25, rounded down to the nearest integer • First Dose Date: Date of first exposure to any study medication ( CRS- 207, Cy, or chemotherapy) • Last Dose Date: The last date which the subject was exposed to any study medication as recorded on the case report form ( CRF) • Study Day : Elapsed time from First Dose Date measured in days and defined as: • Study Day = Event Date – First Dose Date + 1, for events occurring on or after the First Dose Date • Study Day = Event Date – First Dose Date, for events occurring before the First Dose Date • Baseline: Last observation prior to f irst dose of study medication • Treatment Course 1: T reatment Course 1 is defined as the sequence of two CRS- 207 prime vaccinations (with or without low -dose Cy); chemotherapy treatments (up to six cycles); two post -chemotherapy boost vaccinations; EOC follow- up • End of Course : End of the treatment course for subjects that do not receive MV; for subjects that receive MV, the visit following the last administration of MV • End of Study: May occur when a subject discontinues the study. The EOS visit is to take place 28 days (4 weeks) after last dose of study medication. • Study Periods: • Treatment Period: The Treatment Period includes the time from first dose through the EOS safety visit occurring 28 days after the final study medication dose. • Duration of Treatment Exposure: Latest of (Date of EOS visit, Last Dose Date + 28) – First Dose Date + 1. It is assumed that EOS visit occurs approximately 28 days after the final dose of study medication; the EOS visit represents the latest date for which a new AE can be observed/recorded for a subject. Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 15 of 24 04MAY2018 • Percentage Change from Baseline in Tumor Thickness per mRECIST : (total tumor thickness at post -baseline visit – baseline total tumor thickness) / (baseline total tumor thickness) 5.2.3. Adjustments for Covariates Not applicable.